Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Bannwarth

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Therapie|October 28, 2011
[Pharmacological management of inflammatory rheumatic conditions]Bernard Bannwarth
Gastroenterologie Clinique Et Biologique|September 16, 2004
[Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity]Bernard Bannwarth
Drug Safety|May 20, 2008
Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerabilityBernard Bannwarth
Arthritis and Rheumatism|July 9, 2003
Concerns about gastrointestinal safety of acetaminophen: comment on the article by Rahme et alBernard Bannwarth
Presse Medicale (Paris, France : 1983)|October 25, 2002
[Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]Bernard Bannwarth
Drug Safety|March 1, 2005
Do selective cyclo-oxygenase-2 inhibitors have a future?Bernard Bannwarth
Joint Bone Spine|December 22, 2009
Irrelevance of the WHO analgesic ladder for managing rheumatic painBernard Bannwarth
Arthritis and Rheumatism|February 1, 2007
Transdermal fentanyl in patients with osteoarthritis: comment on the article by Langford et alBernard Bannwarth
Expert Opinion on Drug Safety|December 3, 2010
Clinical safety of tocilizumab in rheumatoid arthritisBernard Bannwarth, Christophe Richez
Gastroenterologie Clinique Et Biologique|September 16, 2004
[Management of the digestive risk in patients treated with NSAIDs. Synthesis and perspectives]Gérard Thiéfin, Bernard Bannwarth
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Therapie|October 28, 2011
[Pharmacological management of inflammatory rheumatic conditions]Bernard Bannwarth
Gastroenterologie Clinique Et Biologique|September 16, 2004
[Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity]Bernard Bannwarth
Drug Safety|May 20, 2008
Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerabilityBernard Bannwarth
Arthritis and Rheumatism|July 9, 2003
Concerns about gastrointestinal safety of acetaminophen: comment on the article by Rahme et alBernard Bannwarth
Presse Medicale (Paris, France : 1983)|October 25, 2002
[Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]Bernard Bannwarth
Drug Safety|March 1, 2005
Do selective cyclo-oxygenase-2 inhibitors have a future?Bernard Bannwarth
Joint Bone Spine|December 22, 2009
Irrelevance of the WHO analgesic ladder for managing rheumatic painBernard Bannwarth
Arthritis and Rheumatism|February 1, 2007
Transdermal fentanyl in patients with osteoarthritis: comment on the article by Langford et alBernard Bannwarth
Expert Opinion on Drug Safety|December 3, 2010
Clinical safety of tocilizumab in rheumatoid arthritisBernard Bannwarth, Christophe Richez
Gastroenterologie Clinique Et Biologique|September 16, 2004
[Management of the digestive risk in patients treated with NSAIDs. Synthesis and perspectives]Gérard Thiéfin, Bernard Bannwarth
Pageof 6